



NDA 20-103/S-031
NDA 20-605/S-015
NDA 20-781/S-015
NDA 20-007/S-044

SUPPLEMENT APPROVAL

GlaxoSmithKline
Attention: Amita Chaudhari, M.Sc.
Manager, Global Regulatory Affairs
1250 South Collegeville Rd.
UP4400
Collegeville, PA 19426

Dear Ms. Amita:

Please refer to your Supplemental New Drug Application (sNDA) dated and received June 7, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following.

NDA	Supplement	Drug Product
20-103	S-031	Zofran (ondansetron hydrochloride) Tablets
20-605	S-015	Zofran (ondansetron hydrochloride) Oral Solution
20-781	S-015	Zofran ODT (ondansetron) Orally Disintegrating Tablets
20-007	S-044	Zofran (ondansetron hydrochloride) Injection

We acknowledge receipt of your amendments dated October 24, 2013.

These “Changes Being Effected” supplemental new drug applications provide for the addition of Stevens-Johnson syndrome and toxic epidermal necrolysis to the Adverse Reactions sections of the package inserts.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at

NDA 20-103/S-031
NDA 20-605/S-015
NDA 20-781/S-015
NDA 20-007/S-044
Page 2

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Heather Buck, Regulatory Project Manager, at (301) 796-1413.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H.
Deputy Director for Safety
Division of Gastroenterology and Inborn Errors Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURES: Content of Labeling (Package Inserts)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOYCE A KORVICK
12/10/2013